Bills › 90th General Assembly
Relating to Lyme disease, including notice and consent provisions required for Lyme disease testing, and continuing education requirements for health care providers
Topics:Health care
Same legislation: HF 2591
Where it is now
- Done: IntroducedFebruary 5, 2024
- Done: SubcommitteeFebruary 6, 2024
- Done: House committeeFebruary 14, 2024
- Next: Passes the House
- Next: Senate committee
- Next: Passes the Senate
- Next: To the Governor
- Next: Signed into law
Became HF 2591 → Its progress continues under the new number. Go to HF 2591 What’s a funnel?
What’s in it
This bill relates to notice and consent requirements for testing and treatment of Lyme disease. The bill provides that a health care provider who draws the blood of a patient to perform a laboratory test for the presence of Lyme disease or a medical laboratory that performs a laboratory test for the presence of Lyme disease shall provide the written notice prescribed in the bill to the patient at the time the patient’s blood is drawn. The notice must include statements that: current laboratory testing for the presence of Lyme disease can be problematic and standard laboratory tests often result in false negative and false positive results; that if testing is performed too early, the patient may not have produced enough antibodies to be considered positive because the patient’s immune response requires time to develop antibodies; that if the patient is tested for the presence of Lyme disease and the results are negative, this does not necessarily mean the patient does not have Lyme disease; and that if the patient continues to experience unexplained symptoms, the patient should contact the patient’s health care provider and inquire about the appropriateness of retesting or initial or additional treatment.
Read the full explanation
If at any time the department of health and human services (HHS) finds there are significant differences between the content of the required notice and the most recent medical evidence on Lyme disease testing, HHS may adopt administrative rules to amend the content of the notice to reflect the most recent medical evidence. Additionally, the provision by a health care provider or medical laboratory of the notice required under the bill shall not be the sole basis for a cause of action or licensee discipline. “Health care provider” and “medical laboratory” are defined in the bill. The bill also requires professional licensing boards for health care providers to develop, and health care providers to complete, continuing education requirements regarding treatment strategies to assist patients with prolonged symptoms due to Lyme disease in managing and recovering from these prolonged symptoms. The bill also amends a Code provision relating to Lyme disease treatment and exemption from licensee discipline to provide that a health care provider as defined under the bill shall not be subject to licensee discipline under Code chapter 147 (general provisions, health-related professions) or the health licensing board’s enabling statute solely on the basis of the provision of the notice required under the bill.
From the explanation printed with the bill as introduced, written by the Legislative Services Agency. Amendments adopted later aren’t reflected. Full bill text
House subcommittee
Named February 6, 2024. On February 12, 2024 it recommended passage. Vote Total: 2-0.
Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part
Iowa Code it changes
Amends§147.56
Read from the bill as introduced. Each links to every bill touching that chapter of the Iowa Code. How the Code works
Lobbying
0 for · 0 against · 5 undecided · Who →
Family tree
Where this legislation came from and where it went: earlier tries, the versions it moved through this Assembly, and later bills built on it.
90th General Assembly
Earlier and later bills are matched by wording or an identical title; check the text to be sure it’s the same idea.